SPHK1 and adrenocortical carcinoma, hereditary: Therefore, Nidogen 1, Sphk1 and the type III TGF-β receptor could therefore serve as a novel theragnostic in AdCC, potentially in combination with an Akt- or NF-κB-inhibitor; respectively.